Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
62 hedge funds and large institutions have $91M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 13 closing their positions.
69% more capital invested
Capital invested by funds: $54M → $91M (+$37M)
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
7% more funds holding
Funds holding: 58 → 62 (+4)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
100% less call options, than puts
Call options by funds: $20K | Put options by funds: $4.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.61M |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$997K |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$829K |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
+$513K |
| 5 |
Two Sigma Investments
New York
|
+$287K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$3.26M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.14M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.14M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$629K |
| 5 |
Citigroup
New York
|
-$589K |
KNTE Hedge Fund Activity: Q4 2023 in Review
62 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q4 2023, worth a combined $91M — up 69% from $54M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KNTE positions and 13 closed out — a net gain of 4 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $4.61M. The largest seller was Nextech Invest, exiting entirely with an estimated $3.26M sold.
- 62 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q4 2023, up from 58 in Q3 2023.
- Funds reported $91M of Kinnate Biopharma Inc. Common Stock stock for Q4 2023, up 69% quarter-over-quarter.
- 17 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q4 2023 and 13 closed out, a net change of +4 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q4 2023 was Tang Capital Management, an estimated $4.61M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q4 2023 was Nextech Invest, an estimated $3.26M sold.
Based on aggregated 13F filings for Q4 2023.